A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Allergan

Status: Completed

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: Bimatoprost

Study type: Observational

Funder types: Industry

Identifiers

NCT01646151

MAF/AGN/OPH/GLA/033

Details and patient eligibility

About

An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Visits and treatment are per normal clinical practice.

Enrollment: 2,580 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of POAG or OHT
• Previous use of IOP-lowering medication

Exclusion criteria

• None

Trial design

2,580 participants in 1 patient group

Bimatoprost

Description:

Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.

Treatment:

Drug: Bimatoprost